Get the Stockscreener App
5.58
3.63%
-0.21
After Hours:
5.52
-0.06
-1.08%
Cns Pharmaceuticals Inc stock is traded at $5.58, with a volume of 33,789.
It is down -3.63% in the last 24 hours and up +2.20% over the past month.
CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells that make up the supportive tissue of the brain.
See More
Previous Close:
$5.79
Open:
$5.52
24h Volume:
33,789
Relative Volume:
1.04
Market Cap:
$3.46M
Revenue:
-
Net Income/Loss:
$-17.06M
P/E Ratio:
-0.0789
EPS:
-70.7173
Net Cash Flow:
$-14.18M
1W Performance:
-7.62%
1M Performance:
+2.20%
6M Performance:
-26.77%
1Y Performance:
-90.68%
1-Day Range:
$5.50
$5.825
1-Week Range:
$5.50
$6.4096
52-Week Range:
$4.93
$114.00
Cns Pharmaceuticals Inc Stock (CNSP) Company Profile
Name
Cns Pharmaceuticals Inc
Sector
Industry
Phone
1-800-946-9185
Address
2100 WEST LOOP SOUTH, HOUSTON
Compare CNSP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CNSP
Cns Pharmaceuticals Inc
|
5.58 | 3.59M | 0 | -17.06M | -14.18M | -70.72 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.90 | 120.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.45 | 78.77B | 14.34B | 4.50B | 3.88B | 41.57 |
|
ARGX
Argen X Se Adr
|
840.50 | 52.46B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
338.06 | 45.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
340.38 | 38.73B | 4.98B | 69.59M | 525.67M | 0.5197 |
Cns Pharmaceuticals Inc Stock (CNSP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-28-20 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Aug-24-20 | Initiated | Ladenburg Thalmann | Buy |
Cns Pharmaceuticals Inc Stock (CNSP) Latest News
CNS Pharmaceuticals says priority ‘is to transform’ how company operates - TipRanks
CNS Pharmaceuticals’ new CEO outlines strategic overhaul By Investing.com - Investing.com Canada
CNS Pharmaceuticals (NASDAQ: CNSP) Issues Shareholder Letter Outlining Strategic Review and Focus on TPI 287 - Digital Journal
CNS Pharmaceuticals Announces Strategic Review Focused on Lead Drug Candidate TPI 287 - citybuzz -
CNS Pharmaceuticals (CNSP) CEO Outlines Strategic Vision for Fut - GuruFocus
CNS Pharmaceuticals’ new CEO outlines strategic overhaul - Investing.com
CNS Pharmaceuticals Issues Letter to Shareholders - ACCESS Newswire
New CNS Pharmaceuticals CEO launches broad review built around lead cancer drug - Stock Titan
Breakout Move: Is CNS Pharmaceuticals Inc stock good for income investorsMarket Volume Report & Daily Risk Controlled Trade Plans - baoquankhu1.vn
CNS Pharmaceuticals (NASDAQ:CNSP) Stock Price Up 3.3% – What’s Next? - Defense World
Is CNS Pharmaceuticals Inc. being accumulated by smart money2025 Major Catalysts & Precise Buy Zone Identification - bollywoodhelpline.com
CNS Pharma Stock Up Over 30% - Nasdaq
Weekly Trades: Is CNS Pharmaceuticals Inc in a long term uptrendJuly 2025 Fed Impact & Verified Short-Term Plans - baoquankhu1.vn
How CNS Pharmaceuticals Inc. stock compares to market leadersForecast Cut & AI Optimized Trading Strategy Guides - ulpravda.ru
How CNS Pharmaceuticals Inc. stock reacts to global recession fears2025 Price Targets & Growth Focused Investment Plans - Улправда
How CNS Pharmaceuticals Inc. stock performs after earningsJuly 2025 Summary & Detailed Earnings Play Alerts - Улправда
Should I hold or sell CNS Pharmaceuticals Inc. stock in 2025Earnings Risk Summary & Reliable Volume Spike Alerts - Улправда
Dividend Watch: How CNS Pharmaceuticals Inc. stock performs in rate cut cycles2025 Investor Takeaways & Accurate Trade Setup Notifications - Улправда
CNS Pharmaceuticals shares dip after CEO departure announcement - MSN
CNS Pharmaceuticals Inc. (CNSP) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
CNS Pharmaceuticals (NASDAQ:CNSP) Stock Price Down 0.5% – Here’s Why - Defense World
Aug Reactions: How CNS Pharmaceuticals Inc stock performs in rate cut cycles2025 Top Gainers & Capital Efficient Trading Techniques - moha.gov.vn
CNS Pharmaceuticals names Rami Levin as new CEO following John Climaco’s departure - MSN
Whats Driving Tourism Finance Corporation of India Limited Stocks Recent Momentum Key TrendsCandlestick Trading Patterns & High Return Capital Strategies - earlytimes.in
Why CNS Pharmaceuticals Inc. stock is popular among millennialsJuly 2025 Update & Free Risk Controlled Daily Trade Plans - Улправда
Will CNS Pharmaceuticals Inc. stock remain a Wall Street favorite2025 Growth vs Value & Safe Entry Trade Signal Reports - Улправда
Is CNS Pharmaceuticals Inc. stock positioned well for digital economyQuarterly Earnings Report & High Conviction Buy Zone Picks - Улправда
CNSP (CNS Pharmaceuticals) EV-to-OCF : 0.34 (As of Dec. 19, 2025) - GuruFocus
CNSP (CNS Pharmaceuticals) EV-to-OCF : 0.34 (As of Dec. 18, 2025) - GuruFocus
CNS Pharmaceuticals appoints Rami Levin as new CEO, replacing Climaco By Investing.com - Investing.com South Africa
CNS Pharmaceuticals Announces New CEO Appointment - The Globe and Mail
CNS Pharmaceuticals (NASDAQ: CNSP) Appoints Rami Levin as President and CEO - Digital Journal
CNS Pharmaceuticals Appoints Rami Levin as CEO to Advance Brain Cancer Pipeline - citybuzz -
CNS Pharmaceuticals appoints Rami Levin as CEO, John Climaco resigns By Investing.com - Investing.com Australia
CNS Pharmaceuticals appoints Rami Levin as CEO effective Jan 1, 2026 - marketscreener.com
CNS Pharmaceuticals stock falls after CEO steps down - Investing.com India
CNS Pharmaceuticals stock falls after CEO steps down By Investing.com - Investing.com Nigeria
CNS Pharmaceuticals appoints Rami Levin as CEO, John Climaco resigns - Investing.com
CNS Pharmaceuticals Announces CEO Transition - TradingView — Track All Markets
CNS Pharmaceuticals (CNSP) appoints new CEO Rami Levin and outlines Climaco severance - Stock Titan
CNS Pharmaceuticals (CNSP) Appoints New CEO - GuruFocus
CNS Pharmaceuticals appoints Rami Levin as new CEO, replacing Climaco - Investing.com India
Brain cancer drug developer taps new CEO with global track record - Stock Titan
CNS Pharmaceuticals Earnings Notes - Trefis
Cycle buying Applied Therapeutics to develop CNS drugs - BioWorld MedTech
Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at 7th Annual CNS Delivery SummitSlideshow - Seeking Alpha
Cns Pharmaceuticals Inc Stock (CNSP) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.27%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):